EPA cancels pesticide shown to be harmful to unborn babies
The EPA’s emergency ban on the herbicide DCPA, decades after classifying it as a likely carcinogen, prompts broader scrutiny of how long potentially harmful chemicals remain in use and how slowly regulators react to new evidence, especially around fetal toxicity and developmental harm. Commenters contrast U.S. and European regulatory philosophies, debate precaution vs. overreaction in cases like glyphosate, and wrestle with how (or whether) to price in severe health externalities such as birth defects instead of relying on outright bans.
Overall reaction to DCPA ban
- Many welcome the ban, especially given fetal toxicity and birth-defect risks.
- Strong frustration that EPA classified DCPA as a likely carcinogen decades ago yet only now issued an emergency stop-use order.
- Some worry that prohibiting sale may push remaining stock to weaker-regulation countries, citing historical precedents with other pesticides.
Glyphosate comparison and pesticide risk
- Some argue glyphosate should be next, citing repeated patterns: chemicals approved, widely used, then later restricted (DDT, BPA, PFCs, DCPA).
- Others say glyphosate is not comparable: toxicology data suggest relatively low acute toxicity, and classification as “probably carcinogenic” is still debated.
- Distinction raised between pure glyphosate and commercial formulations whose surfactants/adjuvants may be more toxic.
- A meta‑analysis linking glyphosate-based herbicides to non‑Hodgkin lymphoma is mentioned as “compelling” evidence, while others point to sources describing overall low risk.
Regulation: EPA, IARC, and timelines
- Clarification that EPA and IARC use different classification systems and do not bind each other.
- EPA’s “likely carcinogen” category is described as based mainly on animal and mechanistic evidence with limited or no clear human data.
- Some note the U.S. acts more reactively, reopening pesticide reviews roughly every 15 years; calls for more frequent and better-funded re-evaluations.
- Others ask why re-checking is periodic rather than triggered only by new data.
US vs EU regulatory philosophy
- One view: U.S. is more libertarian and reactive; Europe more precautionary and protective of citizens.
- Counterview: EU regulation often protects domestic agriculture/economic interests rather than people; skepticism that Europe is truly safer overall.
- Examples surface on both sides (pesticide bans, antibiotics access) without clear resolution.
Externalities and moral limits of pricing harm
- Debate on whether harms to fetuses/unborn children could be “priced in” as an externality vs being inherently moral/non‑monetizable.
- Some propose actuarial-style costing (medical costs, lost earnings, disability-adjusted life years).
- Others stress practical difficulties: attribution, slow or subtle harms, and unmeasurable losses (e.g., reduced IQ, lost potential).
- Several argue some harms justify outright bans rather than taxes or price adjustments.
Language: “unborn babies” vs “fetuses”
- Disagreement over terminology: some see “unborn babies” as politically loaded, typically used by anti‑abortion advocates.
- Others argue it’s a straightforward humanizing term with historical analogs and that focusing on wording here distracts from pesticide safety.
- Concern that language shapes public attitudes about abortion and fetal status, so neutral terms like “fetus” are preferred by some.